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Objective: The process of arteriogenesis is driven by various growth factors including vascular endothelial growth factor (VEGF)-A,
which mediates its activity through VEGFR-2 (Flk-1/KDR) on endothelial cells and through VEGFR-1 (Flt-1) on endothelial cells and
monocytes. The purpose of this study was to identify which of the VEGF receptors are involved in arteriogenesis in vivo. Methods:
Collateral vessel growth was induced by femoral artery ligation in a mouse model of hindlimb ischemia. Following ligation, Balb/c mice
were treated with different growth factors (VEGF-A, VEGF-E, PlGF-2, VEGF-E plus PlGF-2 or VEGF-A plus PlGF-2, activating either
VEGFR-1, VEGFR-2, or both). After 1 week of treatment, hindlimb perfusion was assessed by perfusion scintigraphy using Tc-99m-MIBI.
Results: The strongest improvement of regional perfusion was achieved by simultaneous activation of VEGFR-1 and VEGFR-2, using either
VEGF-A or VEGF-A plus PlGF-2, with elevation of relative perfusion in the ischemic limbs from 0.61 to 0.83. The partial restoration in
perfusion was associated with morphological changes typical for arteriogenesis. Moreover, specific inhibition of both VEGF-receptors using
ZK 202650 resulted in a significant inhibition of arteriogenesis, indicating an active role of the VEGF system in compensatory arteriogenesis.
Conclusion: The coordinated activation of both VEGFR-1 and VEGFR-2 represents a more potent arteriogenesic stimulus compared to the
isolated activation of either one of these two receptors. These data imply that the activation of both monocytes and endothelial cells is
necessary to obtain a maximal VEGF-induced activation of arteriogenesis.
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74, 01307 Dresden, Germany.process is called arteriogenesis anddescribes the activegrowth
of arterioles into arteries allowing a significant increase of
regional blood flow [1].While the cellular andmolecular basis
of arteriogenesis has partly been clarified [1,2], the relative
functional importance of certain growth factors including
vascular endothelial growth factor (VEGF) remains to be
elucidated. Likewise, the involvement of monocytes has been
demonstrated in the process of arteriogenesis and there are
models explaining the functional impact of monocytes during
arteriogenesis as reservoirs and bioreactors of various growth
factors [3]. However, it remains to be shown to which degree
monocytes are contributing to the growth of arterioles.ed by Elsevier B.V. All rights reserved.
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vascular growth in a large variety of different models.
In a rabbit model of hindlimb ischemia, therapeutic
application of VEGF-A was shown to stimulate limb
perfusion by increasing capillary density (angiogenesis)
and collateral size [4]. However, the mechanism of action
of VEGF-A in the stimulation of arteriogenesis remains to
be elucidated.
VEGF-A can bind to both VEGFR-1 (Flt-1) and
VEGFR-2 (Flk-1). Based on the distribution pattern of
these two VEGF receptors, VEGF-A stimulates not only
endothelial cells that express both of these receptors [5], but
also monocytes that carry functional VEGFR-1 capable of
mediating monocyte chemotaxis [6]. The recent discovery
of the orf-virus encoded VEGF-E that can induce angio-
genesis by exclusive binding to VEGFR-2 [7–9] opens the
possibility of the isolated activation of VEGFR-2 in endo-
thelial cells. Whether this is sufficient to enhance limb
perfusion by stimulating angiogenesis and/or arteriogenesis
remains to be shown. In addition, placenta growth factor-2
(PlGF-2), another member of the VEGF family, can be used
to stimulate VEGFR-1 on both cell types [10], which was
sufficient to stimulate arteriogenesis in PlGF / mice [11].
Finally, a direct effect of VEGF-A on activated smooth
muscle cells cannot be excluded as activated smooth
muscle cells in injured arteries had been shown to express
VEGFR-1 [12].
In the present study, we investigated whether VEGF-E
(and therefore activation of VEGFR-2) is sufficient to
induce arteriogenesis. Moreover, we studied, whether the
action of VEGF-A can further be enhanced by additional
stimulation of VEGFR-1 using PlGF-2. To proof the role
of VEGF and its receptors, the tyrosine kinases of both
receptors were inhibited using either ZK 202650 or spe-
cific neutralizing antibodies MF 1 and DC 101. To answer
these questions, a mouse model was established, which
precisely allows the quantitation of blood flow in hind
limb scintigraphy.2. Materials and methods
2.1. Mouse hindlimb model
A mouse model of hindlimb ischemia was established.
All animal work was approved by the governmental author-
ity (Regierungspra¨sidium Tu¨bingen) and supervised by
institutional animal protection officials. The investigation
conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Indtitutes of Health
(NIH publication No. 85-23, revised 1996). We used 12
weeks old Balb/C mice weighting between 26 and 30 g. The
mice were kept pathogen-free in groups of five in a strict 12-
h night and day cycle. In brief, unilateral ligation of the right
femoral artery was performed under short-term anaesthesia.
The anaesthetic contained 104 mg/kg Ketamin (KetanestRS, Parke-Davis) and 16 mg/kg Xylazin (RompunR 2%,
Bayer) and was given as a single bolus of 0.27 ml into
the peritoneal cavity.
Prior to perfusion analysis, exactly 7 days following
ligation (see below), the animals were treated for the whole
period with repeated injections of either recombinant growth
factor or carrier solution (0.1 mg/ml mouse serum albumin
(Sigma) in phosphate buffered saline) into the tail vein every
12 h starting immediately after femoral artery ligation. The
mice were given either VEGF-A (500 ng bid), VEGF-E (500
ng bid), PlGF-2 (1000 ng bid), a combination of VEGF-E
and PlGF-2 or a combination of VEGF-A and PlGF-2 (same
doses as in the case of isolated application). VEGF-A and
PlGF-2 were purchased from Reliatech, Germany. Recom-
binant VEGF-E was generated in Escherichia coli as previ-
ously described [7]. The biological activity of all the
different recombinant proteins has been verified by in vitro
experiments prior to application to animals. Each group
consisted of a total of seven animals.
Another series of mice was treated with ZK 202650
(Schering, Berlin). The substance was applied subcutane-
ously, starting 2 days prior to ligation and repeated every
other day. Three groups were investigated, 20 mg/kg
ZK202650 (n = 4), 50 mg/kg (n = 7) and placebo (n = 7).
In another series, neutralizing antibodies directed against
VEGFR-1 (MF-1, n = 9) and VEGFR-2 (DC-101, n = 10),
both from Imclone, were applied into the peritoneal cavity
to block the activity of VEGF.
2.2. In vivo perfusion measurement using scintigraphy
Perfusion analysis was previously described in rats and
validated using coloured microspheres [13]. In the present
study, perfusion analysis was transferred for the first time on
a mouse model. The method was validated by perfusion
assessment in a group (n = 7) of non-operated and non-
treated animals, which had equal perfusion in both hind
limbs (ratio 0.98F 0.11). Furthermore, a series with sham
operated animals vs. animals with a ligated limb
(0.54F 0.23 vs. 0.91F 0.11, p < 0.04) was scanned. Perfu-
sion analysis was performed 7 days after femoral artery
ligation. The discriminatory power of this method was
maximal at day 7 and better than on day 4 or on day 14
(own, unpublished data). Quantitative perfusion imaging
was performed using i.v. injection of Hexakis(2-methoxyi-
sobutylisonitrile)-technetium-99m (Tc-99m-MIBI) (Cardi-
oliteR, Dupont Pharma), a lipophilic perfusion marker
(bolus of 200 Al containing a dose of 50–60 MBq) and
quantitation on a gamma camera (BasicamR, Siemens,
using the ICON software package). In order to exclude
interindividual differences as well as investigator-dependent
bias, the ratios between ligated and non-ligated limb were
measured in a standardised fashion (see definition of target
area in Fig. 1A). Three investigators confirmed placement of
the regions of interest prior to calculation. Statistics were
done using ANOVA. The data are presented as the ratio of
Fig. 1. Quantitative assessment of mouse hind limb perfusion 7 days
following ligation of the right femoral artery. (A) Representative perfusion
images (with the target area marked blue) are shown for a VEGF-A treated
mouse (left) and for an untreated mouse 7 days after ligation of the femoral
artery (right). (B) The relative perfusion index is given as an average of
seven animals in each group showing least square mean and 95% CI.
*p< 0.05 compared to control using ANOVA.
Fig. 2. Relative perfusion of right over left hind limb after seven days of
ligation of the right femoral artery was assessed by scintigraphy. Three
groups receiving placebo, ZK 202650 20 mg/kg and ZK 202650 50 mg/kg
were compared. The mean perfusion and S.D. is presented. At 50 mg/kg,
the restoration of perfusion was significantly decreased compared to
placebo.
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limb including the 95 % confidence interval.
2.3. Macro- and micromorphological evaluation of collat-
eral arteries
2.3.1. Estimation of a collateral score
Sixteen hours following perfusion imaging, the mice
were sacrificed during anaesthesia. The aorta was cannu-
lated through the left ventricle using a 24 G catheter
(InsyteR 24 G 0.75, Becton Dickinson) followed by
injection of 2 ml saline, 1 ml heparin (5000 I.U. Heparin-
Natrium, B. Braun Melsungen), 2 ml adenosine (6 mg) for
vasodilation and 1 ml of a bismuth contrast agent to
visualise the vascular system. The contrast agent was a
mixture of bismuth (III) nitrate and gelatine, produced in our
laboratory. Photographs were taken using a Contax 167
attached to the operating microscope (OPMI-1, Carl Zeiss,
Germany) (compare Fig. 3A–D). The extent of the collat-
eral artery growth was semiquantitatively estimated by five
investigators using a standard assessment protocol (see Fig.
3E, F).2.3.2. Immunofluorescence analysis of monocytes during
arteriogenesis
Subsequently, the collateral arteries were dissected out
and immediately deep-frozen using liquid nitrogen. Histo-
logical analysis was performed for the presence of CD11b
(Mac-1a chain) positive leukocytes using the FlTC-conju-
gated (Flourescein Isothiocyanate Isomer I conjugated) anti-
mouse CD11b antibody (PharMingen International) and
standard protocols. Photomicrographs were taken using a
fluorescence microscope (Leica), the collateral diameter was
quantitatively assessed.3. Results
3.1. The activation of both VEGFR-1 and VEGFR-2 using
VEGF-A is necessary to induce significant enhancement of
limb perfusion following femoral artery ligation
Recombinant VEGF and PlGF were applied in our hind
limb model at concentrations that had already been reported
to result in a positive biological response elsewhere. The
strongest improvement of regional perfusion was achieved
by simultaneous activation of VEGFR-1 and VEGFR-2
using VEGF-A, applied for 7 days twice a day. Relative
perfusion 1 week after femoral artery ligation could be
elevated from 0.61 (95% CI: 0.52–0.70) in the control group
to 0.83 (95% CI: 0.74–0.92) in the VEGF-A treated group
( p = 0.0088) and to 0.82 (95% CI: 0.73–0.91) in the group
receiving both VEGF-A and PlGF-2 ( p= 0.0022) (Fig. 1B).
The isolated activation of VEGFR-1 using PlGF-2 resulted
in a moderately elevated relative perfusion of 0.66 (95% CI:
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VEGFR-2 using VEGF-E resulted in a relative perfusion
of 0.65 (95% CI: 0.56–0.73) ( p>0.5). In both instances of
activation of a single VEGF receptor, perfusion in the
ischemic limb was not significantly different from the
untreated control group. The same was observed for the
simultaneous injection of PlGF-2 and VEGF-E, which did
not result in the enhancement of limb perfusion. Primary data
obtained on the gamma camera already indicate reduced
perfusion of the ligated hindlimb in the control group
without growth factor stimulation (Fig. 1A, right panel).
3.2. The activation of VEGF receptors is involved in
compensatory arteriogenesis
The application of ZK 202650, an inhibitor of VEGF
receptor tyrosine kinase activity, resulted in a reduction ofFig. 3. Anatomy of collateral vessels in the mouse hindlimb model. Visualisation b
days following ligation of the right femoral artery (A, C). The situation of the corre
D). (A) Ligation of the femoral artery and repeated iv-injections of VEGF-A is acc
collateral vessel reaches the one of the distal femoral artery. The typical pattern of
highlighted by a circle. (B) No collateral artery growth can be seen on the non-lig
setting in A, however, the animal received repeated injections of saline buffer. Pleas
non-ligated contralateral control (D). However, the diameter of the collateral
Semiquantitative assessment of the size of collateral arteries in mice secondary to
scale ranging from 1 (preformed, not-grown collateral vessel) to 6 (collateral arte
shown for the PlGF-2 +VEGF-A group, which had shown the strongest effect ofperfusion on day 7 following ligation. While restoration of
blood flow was not compromised in the control group
(0.72F 0.14), application of ZK 202650 significantly de-
creased perfusion in a concentration-dependent fashion read-
ing 0.5F 0.14 ( p = 0.0055) at a concentration of 50 mg/kg.
(0.55F 0.14, p = 0.0055) (Fig. 2). Likewise, experiments
were performed using neutralizing antibodies to both
VEGF-receptors. No effect on perfusion was apparent in
this series of experiments (data not shown).
3.3. Enhanced limb perfusion 7 days following femoral
artery ligation is associated with arteriogenesis
The growth of collateral arteries, i.e. extent of arterio-
genesis, can be visualised by microphotography and semi-
quantitatively analysed following injection of bismuth-
containing contrast agent into the aorta. Typical examplesy microphotography after injection of bismuth contrast agent into the aorta 7
sponding contralateral, non-ligated control side is shown for comparison (B,
ompanied from impressive growth of collateral vessels. The diameter of the
tortuosity in the grown collateral vessel is noted. The site of the ligation is
ated contralateral side of the mouse receiving VEGF-A. (C) Similar to the
e notice that there is some growth of the collateral vessel as compared to the
vessel is much smaller than in the VEGF-A-treated animals (A). (E,F)
femoral artery ligation and iv-treatment with growth factors is given on a
ry measuring the same size as the feeding artery). Representative data are
the enhancement of perfusion in the ligated limb.
Fig. 4. Mac-1 positive leukocytes in a preformed collateral artery (A) and
infiltrating the growing collateral artery 7 days following ligation of the
femoral artery (B). Bars indicate 20 Am. Original magnification: 100 .
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measured 3 in the control group and 5.2 in the PlGF-2 plus
VEGF-A group, which was the group with the strongest
improvement following growth factor application (Fig. 3E),
which measured the highest level of limb perfusion. Mac-1
positive leukocytes are hardly detectable in a preformed
collateral artery (Fig. 4A), while there are abundant CD11b
(Mac-1a chain) positive cells infiltrating the wall of the
growing collateral artery 7 days following ligation of the
femoral artery (Fig. 4B). This cellular infiltration is associ-
ated with an enhancement of collateral diameter from
0.079F 0.012 to 0.13F 0.013 mm (n = 20, p < 0.05), as
assessed by histomorphometry.4. Discussion
Using a mouse hindlimb model of regional ischemia, we
have found that the concerted activation of both VEGFR-1
and VEGFR-2 using prolonged and repeated administration
of VEGF-A was sufficient to enhance limb perfusion and to
stimulate arteriogenesis. In contrast, the isolated activation
of VEGFR-1 using PlGF-2 or the isolated activation ofVEGFR-2 using VEGF-E was not sufficient to significantly
enhance perfusion of the ischemic extremity in Balb/C mice.
The positive effect of VEGF-Awas on a similar level as the
effect of the combined application of VEGF-A and PlGF-2.
These data suggest that VEGF-A is a potent arteriogenic
stimulus and that the coordinated activation of VEGFR-1
and VEGFR-2 is necessary for the stimulation of arterio-
genesis in the hindlimb model.
The simultaneous, but isolated, i.e. not concerted
activation of VEGFR-1 using PlGF-2 and of VEGFR-2
using VEGF-E, was not associated with a detectable
arteriogenic stimulus in our model. There are at least
two possible explanations for this finding: (1) In contrast
to the potent arteriogenic stimulus VEGF-A, the combi-
nation of VEGF-E plus PlGF-2 is unable to form VEGF
receptor heterodimers. Such heterodimers had long been
postulated [5] and have recently been demonstrated [14].
Our in vivo data are compatible with the interesting
hypothesis that a relevant arteriogenic stimulus requires
the formation of VEGFR-1/VEGFR-2 heterodimers. (2)
We cannot exclude the possibility that the combination of
PlGF-2 and VEGF-E was lacking a functional effect in
our model on the basis of inadequate dosing or inade-
quate action of VEGF-E secondary to rapid degradation.
However, no reagents are currently available to prove this
issue.
Assuming a transitor function of VEGF-receptors during
arteriogenesis. The isolated activation of VEGFR-1 using
PlGF-2 is not sufficient in our Balb/C wild-type mice to
enhance arteriogenesis and tissue perfusion. This situation is
different from the situation in PlGF / mice, however,
which show an impaired arteriogenic response secondary to
acute ischemia that can be overcome by the application of
PlGF-2 [11]. This could be explained by a functional
interaction between VEGFR-1 and VEGFR-2 inside the
endothelial cell. The reduced level of VEGFR-1 activation
in PlGF / mice is associated with a reduced functional
activity of VEGFR-2, which is not the case in wild-type
mice, as we have just shown [14].
The most potent arteriogenic stimulus in our model were
VEGF-A and the combination of VEGF-A and PlGF-2,
respectively. It activates both VEGFR-1 and VEGFR-2.
Though VEGFR-1 is being expressed on endothelial cells
as well as on monocytes, both cell systems seem to play a
crucial role in regulating arteriogenesis.
Monocytes have been suggested to play a critical role
in the process of arteriogenesis, and we can provide
further evidence in our study. This is sustained by the
observation that both receptors (VEGFR-1 and VEGFR-2)
need to be activated in order to obtain a significant effect
on the improvement of limb perfusion through growing
collateral arteries. However, the data of our study clearly
suggest that the activation of monocytes via VEGFR-1 is
not sufficient to induce arteriogenesis as the application
of PlGF-2 (or the application of PlGF-2 plus VEGF-E)
did not result in enhanced limb perfusion. In conse-
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crucial role in the induction of arteriogenesis. In contrast
to monocytes, endothelial activation is mediated via both
VEGFR-1 and VEGFR-2 [5]. VEGFR-1 has been recog-
nized as an important positive mediator of the VEGF-
signal in endothelial cells [14,15] (and own, unpublished
data). Moreover, the role of VEGFR-1 on activated
vascular smooth muscle cells in arteriogenesis deserves
further analysis.
One argument in favour of a critical role of monocytes in
the process of arteriogenesis came from the observation that
monocyte activation using LPS or MCP-1 stimulates arterio-
genesis [3]. It remains to be shown, however, whether
endogenous MCP-1 plays a role in arteriogenesis. This
question is critical in the light of the recent observations that
(i) MCP-1 directly stimulates endothelial cells [16,17] and
that (ii) MCP-1 can initiate a potent angiogenic stimulus [18].
It will be an important task of future studies to definitely
clarify the role of monocytes in specific and the role of
circulating cells in general in the process of arteriogenesis.
The selective blockage of the VEGF receptor tyrosine
kinases using ZK 202650 resulted in a decreased perfusion
after 7 days indicating a decrease of the arteriogenic
response. These data clearly suggest that VEGF plays an
active role in compensatory arteriogenesis in vivo. In
contrast, the application of monoclonal antibodies neutral-
izing the activity of either VEGFR-1 or VEGFR-2 or both
showed no effect on perfusion. It is likely that these anti-
bodies were inefficient due to either inappropriate pharma-
cokinetics, degradation or poor local tissue availability.
The quantitative analysis of limb perfusion has until
recently not been possible in mice. In larger animals such
as rabbits, perfusion analysis was possible when radioac-
tive or coloured microspheres were injected into the arterial
system or when flow measurement devices were used. We
have now adopted Tc-99m-MIBI analysis for quantitative
analysis of limb perfusion in the mouse, a method that can
easily and reproducibly be applied in the mouse model.
Moreover, longitudinal studies are possible using this non-
invasive method. Scintigraphy reflects perfusion of the
hind limb over the full thickness of the limb. This greatly
differs from laser Doppler scanning [19], which assesses
tissue perfusion only to a depth of approximately 200 Am.
It is rather unlikely to assume that skin perfusion really
reflects limb perfusion. Therefore, a nuclear scan using
TC-99m-MIBI should be one of the most valid non-
invasive methods to assess hindlimb perfusion. It is im-
portant to note that the scintigraphic enhancement of
perfusion was paralleled by morphological changes reflect-
ing true arteriogenesis.
Our study demonstrates that the mouse hindlimb model
is suitable to document the functional consequences of
therapeutic arteriogenesis that occur within the first week
after femoral artery ligation. The stimulation of arterio-
genesis using VEGF-A or VEGF-A plus PlGF-2 was safe
and no side effects such as hypotension or edema forma-tion could be observed in our model. Taken together the
isolated activation of either one of the VEGF receptors did
not result in a significant enhancement of perfusion in the
mouse hindlimb model. In contrast, the simultaneous
activation of both VEGFR-1 and VEGFR-2, possibly by
heterodimer formation or by coordinated activation of both
homodimers, is associated with a significant enhancement
of regional perfusion. Finally, there is good evidence that
the VEGF system is an important mediator of endogenous
compensatory arteriogenesis, i.e. in the absence of thera-
peutic stimulation.Acknowledgements
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